JP2025508786A5 - - Google Patents

Info

Publication number
JP2025508786A5
JP2025508786A5 JP2024549495A JP2024549495A JP2025508786A5 JP 2025508786 A5 JP2025508786 A5 JP 2025508786A5 JP 2024549495 A JP2024549495 A JP 2024549495A JP 2024549495 A JP2024549495 A JP 2024549495A JP 2025508786 A5 JP2025508786 A5 JP 2025508786A5
Authority
JP
Japan
Prior art keywords
agent
dose
administered
day
dll3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024549495A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508786A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/063010 external-priority patent/WO2023164474A1/en
Publication of JP2025508786A publication Critical patent/JP2025508786A/ja
Publication of JP2025508786A5 publication Critical patent/JP2025508786A5/ja
Pending legal-status Critical Current

Links

JP2024549495A 2022-02-23 2023-02-22 Ｄｌｌ３を標的とする癌治療 Pending JP2025508786A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263313119P 2022-02-23 2022-02-23
US63/313,119 2022-02-23
US202263429311P 2022-12-01 2022-12-01
US63/429,311 2022-12-01
PCT/US2023/063010 WO2023164474A1 (en) 2022-02-23 2023-02-22 Cancer treatment targeting dll3

Publications (2)

Publication Number Publication Date
JP2025508786A JP2025508786A (ja) 2025-04-10
JP2025508786A5 true JP2025508786A5 (enExample) 2026-02-24

Family

ID=85724660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024549495A Pending JP2025508786A (ja) 2022-02-23 2023-02-22 Ｄｌｌ３を標的とする癌治療

Country Status (12)

Country Link
US (1) US20250154247A1 (enExample)
EP (1) EP4482586A1 (enExample)
JP (1) JP2025508786A (enExample)
KR (1) KR20240153575A (enExample)
AU (1) AU2023224210A1 (enExample)
CA (1) CA3252459A1 (enExample)
CL (1) CL2024002529A1 (enExample)
IL (1) IL314195A (enExample)
JO (1) JOP20240188A1 (enExample)
MX (1) MX2024010330A (enExample)
TW (1) TW202342096A (enExample)
WO (1) WO2023164474A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025080688A1 (en) * 2023-10-12 2025-04-17 Amgen Inc. Compositions of bispecific antibody constructs to human dll3 and human cd3
WO2025193578A1 (en) * 2024-03-11 2025-09-18 Amgen Inc. Method of treating brain metastases in subjects with a dll3-positive cancer
WO2026008059A1 (en) * 2024-07-04 2026-01-08 Nanjing Legend Biotech Co., Ltd. Anti-dll3 constructs and uses thereof
WO2026075950A1 (en) * 2024-10-01 2026-04-09 Amgen Inc. Dosing regimen for anti-dll3 agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
ZA200601699B (en) 2003-10-16 2007-05-30 Micromet Ag Multispecific deimmunized CD3-binders
SG10201808730VA (en) 2007-04-03 2018-11-29 Amgen Res Munich Gmbh Cross-species-specific binding domain
MX2018002166A (es) * 2015-08-20 2018-09-12 Abbvie Stemcentrx Llc Conjugados anticuerpo anti-dll3-farmaco y metodos de uso.
EP3732195A4 (en) 2017-12-28 2022-02-09 Chugai Seiyaku Kabushiki Kaisha CYTOTOXICITY-INDUCING THERAPEUTIC
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
EP3819312A1 (en) * 2019-11-10 2021-05-12 Amgen, Inc Dosing regimen for anti-dll3 agents
KR20220162690A (ko) 2020-01-31 2022-12-08 젠선 바이오파마, 인코포레이티드 이중특이성 t 세포 관여항체
CA3173587A1 (en) 2020-03-31 2021-10-07 Chugai Seiyaku Kabushiki-Kaisha Dll3-targeting multispecific antigen-binding molecules and uses thereof
KR20240006585A (ko) * 2021-05-10 2024-01-15 암젠 인크 Dll3 및 pd-1을 표적으로 하는 병용 요법을 위한 투여 요법

Similar Documents

Publication Publication Date Title
JP2024518947A5 (enExample)
JP2022535972A5 (enExample)
Vennepureddy et al. Novel drugs and combination therapies for the treatment of metastatic melanoma
US8003105B2 (en) Method of treating cancer by co-administration of anticancer agents
TWI599369B (zh) 包含阿柏西普（ａｆｌｉｂｅｒｃｅｐｔ）、醛葉酸、５－氟尿嘧啶（５－ｆｕ）及伊立替康（ｉｒｉｎｏｔｅｃａｎ）（ｆｏｌｆｉｒｉ）之組合物
JP2014114288A5 (enExample)
Schwab et al. Development of hemolytic anemia in a nivolumab-treated patient with refractory metastatic squamous cell skin cancer and chronic lymphatic leukemia
JP2023501375A5 (enExample)
CN114746117A (zh) 抗dll3药剂的给药方案
JP2024540275A5 (enExample)
JP2020524670A5 (enExample)
JP2023539625A5 (enExample)
US20200377596A1 (en) Dosing of bispecific t cell engager
JP2021529777A5 (enExample)
EP3920970B1 (en) Method for treating checkpoint inhibitors induced adverse events
Melichar et al. Successful management of infusion reaction accompanying the start of cetuximab therapy
WO2024183817A1 (zh) 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途
US20240207199A1 (en) Fluorocarbon compositions and methods for enhancing immunotherapy
JP2020531437A (ja) ｈａＮＫセツキシマブ併用及び方法
Beisel Alterations in hormone production and utilization during infection
US20250019441A1 (en) Treatment of cancer with anti-ilt2 antibodies
JP2023500045A5 (enExample)
WO2019070497A1 (en) POLY THERAPY AGAINST CANCER
WO2025058453A1 (en) Methods of treating cancer by administering anti-pd-l1/anti-4-1bb bispecific antibodies
JP2020172471A (ja) ヒト化抗ヒトｃｄ２６抗体を含有する医薬組成物